Clinical trial NIVEAU - DSHNHL 2015-01
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2/3 |
| Academic trial | Non |
| Sponsor | LYSA LYmphoma |
| EudraCT Identifier | 2016-002272-27 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03366272 |
| Inclusion criteria | First relapse or progressionAgressive NHLAge > 65 YO or >18 yo and HCT-CI score > 2 or prior ASCT and not eligible for allogeneic transplantation |
| Last update |